Drug Profile
Hepatitis B immune globulin - OMRIX Biopharmaceuticals
Alternative Names: HBIG - OMRIX Biopharmaceuticals; Human-specific anti-hepatitis B immunoglobulin (anti HBsAg) - OMRIX Biopharmaceuticals; Omri-Hep-B; Omri-Hep-B IVLatest Information Update: 13 Jul 2010
Price :
$50
*
At a glance
- Originator OMRIX Biopharmaceuticals
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson